Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The systemic treatment of recurrent ovarian cancer revisited.
Baert T, Ferrero A, Sehouli J, O'Donnell DM, González-Martín A, Joly F, van der Velden J, Blecharz P, Tan DSP, Querleu D, Colombo N, du Bois A, Ledermann JA. Baert T, et al. Among authors: tan dsp. Ann Oncol. 2021 Jun;32(6):710-725. doi: 10.1016/j.annonc.2021.02.015. Epub 2021 Mar 3. Ann Oncol. 2021. PMID: 33675937 Free article. Review.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. Colombo N, et al. Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062. Ann Oncol. 2019. PMID: 31046081 Free article.
TRK inhibitors: managing on-target toxicities.
Lim JSJ, Tan DSP. Lim JSJ, et al. Among authors: tan dsp. Ann Oncol. 2020 Sep;31(9):1109-1111. doi: 10.1016/j.annonc.2020.06.010. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32574723 Free article. No abstract available.
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY, Heong V, Ow S, Chay WY, Kim HS, Choi CH, Goss G, Goh JC, Tai BC, Lim DG, Kaliaperumal N, Au VB, Connolly JE, Kim JW, Friedlander M, Kim K, Tan DS. Ngoi NY, et al. Int J Gynecol Cancer. 2020 Aug;30(8):1239-1242. doi: 10.1136/ijgc-2020-001604. Epub 2020 Jun 25. Int J Gynecol Cancer. 2020. PMID: 32591370 Free PMC article.
Clear cell carcinoma of the endometrium.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher D, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM Jr, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, Bini M, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Among authors: tan dsp. Gynecol Oncol. 2022 Mar;164(3):658-666. doi: 10.1016/j.ygyno.2022.01.012. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063279 Review.
111 results